Please go to the PowerPak homepage
and select a course.
Oncology Pharmacy Consults:
Updates on the Management of Prostate Cancer
Provided by The University of Tennessee College of Pharmacy, in cooperation with ASiM.
Supported by an educational grant from Sanofi.
Prostate cancer (PC) is the leading cause of cancer among men in the United States, and androgen deprivation therapy (ADT) strategies that reduce serum testosterone to castrate levels have been shown to improve survival and other outcomes. However, almost all men with advanced PC eventually progress to castrate-resistant PC and sometimes to metastatic castrate-resistant PC (mCRPC). Recent research has identified new approaches to improve survival and other outcomes for patients with mCRPC, including androgen-blocking drugs, cytotoxic chemotherapy regimens, immunotherapy approaches and radiopharmaceuticals that target skeletal metastases. This enduring case-based activity will provide participants with up-to-date information regarding selecting an appropriate management plan for patients with PC taking into consideration a number of factors including treatment history, symptom severity, and skeletal complications, as well as the unique safety and tolerability issues associated with each approach. It will also highlight the pharmacist's critical role in working with other healthcare professionals to select optimal treatment strategies for patients with mCRPC, identify and manage adverse events (AEs), ensure appropriate monitoring and evaluation, and provide patient education.
The goal of this activity is provide pharmacists with an update and overview of the management of patients with mCRPC. Participants will be better able to develop individualized treatment strategies, anticipate and manage treatment-related AEs, and select appropriate monitoring and dose modification strategies for patients with mCRPC.
This enduring case-based activity is designed for oncology pharmacists, health systems pharmacists, and other pharmacists managing patients with prostate cancer. No prerequisites required.
The University of Tennessee College of Pharmacy takes responsibility for the content, quality, and scientific integrity of this CPE activity. At the conclusion of this activity, the participant should be able to:
- Assess the efficacy of current and emerging therapy options for PC in various patient subtypes.
- Evaluate the role of immunotherapy in PC treatment.
- Identify strategies to mitigate AEs related to prostate cancer and its treatment, including skeletal, cardio-metabolic and renal AEs.
CREDIT DESIGNATION STATEMENT
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Successful completion of this knowledge-based program will provide a statement for 0.5 contact hours of credit (0.05 CEUs) and will be available at the completion of the activity. Successfully completing the activity and receiving credit includes: 1) attending the session; 2) watching, listening to, and participating in the educational activity; 3) completing the self-assessment instrument with a score of at least 70%. UAN: 0064-0000-16-223-H01-P. CE credit will be submitted to the NABP CPE Monitor within 30 days. It is recommended that you check your NABP CPE Monitor e-profile database 30 days after the completion of any CE activity to ensure that your credits are posted.
NABP e-PROFILE ID NUMBER
Pharmacists or pharmacy technicians with questions regarding their NABP e-Profile or CPE Monitor should refer to the FAQ section on the NABP website: http://www.nabp.net/programs/cpe-monitor/cpe-monitor-service. To receive credit for your participation in this activity, all pharmacists must include their NABP e-Profile ID number, along with their date and month of birth. If incorrect information is provided, this will result in "rejected" status from the CPE Monitor. It is the responsibility of the participant to notify The University of Tennessee (within the 60 day submission timeframe) of their corrected information. Otherwise, the completed CE will not be accepted by the CPE Monitor.
Please allow up to 30 days for your credit to appear on CPE Monitor.
Type of Activity: Knowledge
Published: October 28, 2016
Expires: October 28, 2017
Fee Information: There is no fee for this educational activity.
Estimated time to complete activity: 30 minutes
HOW TO EARN CREDIT
Participants must complete the activity as described above in the Credit Designation Statement. To answer the questions, click on your selected choice for each answer then proceed to the next question. We recommend that you print a copy of your answers before you submit them to us. Once completed, click on Submit Post-test at the bottom of the page. Your post-test will automatically be graded. If you successfully complete the post-test (score of 70% or higher), your statement of CE credit will be made available immediately. Click on View Certificate and print the CE statement for your records. If you receive a score lower than 70%, you will receive a message notifying you that you did not pass the post-test. You will have 2 opportunities to pass the post-test.
FULL DISCLOSURE POLICY AFFECTING CPE ACTIVITIES
As an accredited provider by the Accreditation Council for Pharmacy Education (ACPE), it is the policy of The University of Tennessee College of Pharmacy to require the disclosure of the existence of any significant financial interest or any other relationship a faculty member or a sponsor has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The Course Director and Participating Faculty reported the following:
J. Aubrey Waddell, PharmD, FAPhA, BCOP (Chair)
University of Tennessee College of Pharmacy
Blount Memorial Hospital
Dr. Waddell reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
OFF-LABEL PRODUCT DISCUSSION
In accordance with ACPE Criteria for Quality, the audience is advised that discussions in this CPE activity may include reference(s) to unlabeled, unapproved, or investigational uses of therapeutic agents or biomedical devices, including, but not limited to, the following:
- Ketoconazole – indication in case activity does not match US Food and Drug Administration (FDA) labeling. It is included in the National Comprehensive Cancer Network (NCCN) Prostate Cancer Guideline.
- Alendronate – indication in case activity does not match FDA labeling. It is included in the NCCN Prostate Cancer Guideline.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of The University of Tennessee College of Pharmacy name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at firstname.lastname@example.org. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
The following is an interactive case simulation designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CPE post-test, and evaluation. All 3 sections must be completed to receive CPE credit. A statement of credit will be available online immediately following successful completion of the activity.
REQUIRED COMPUTER HARDWARE/SOFTWARE
Please ensure the computer you plan to use meets the following minimum requirements:
- Operating System: Windows 98 or higher & Macintosh 2.2 or higher
- Internet Browser (Mac &/Windows): Internet Explorer 6.0 or higher, Google Chrome, Safari 5.0.6 or higher, Firefox 3.0.3 or higher & Opera 5 or higher
- Broadband Internet connection: Cable, High-speed DSL & any other medium that is internet accessible.
- Peripherals: Computer speakers or headphones
- Monitor Screen Resolution: 320 x 480 or higher
- Media Viewing Requirements: Adobe Reader, Microsoft Power Point, Flash Player & HTML5
TABLE OF CONTENTS
Updates on the Management of Prostate Cancer
J. Aubrey Waddell, PharmD, FAPhA, BCOP
Postassessment and Evaluation